OBJECTIVES: There is considerable controversy regarding the safety of ovarian preservation in @entity420 . The aim of this review is to determine the incidence of @entity43 in @entity1 with @entity420 (particularly in early-stage disease), identify risk factors for @entity43 and evaluate the outcome of @entity1 with ovarian preservation. METHODS: Relevant articles were identified from MEDLINE and EMBASE. Included studies were prospective or retrospective cohort and cross-sectional studies analyzing the incidence of @entity43 in @entity420 and studies evaluating the outcome of @entity1 with ovarian preservation. RESULTS: Ten articles including 1204 @entity1 evaluated the frequency of @entity43 . The incidence considering all FIGO stages was 3.7% (range: 0%-12.9%) and the incidence in FIGO stage IB was 2% (range: 0.8%-3.2%). Six articles evaluated the outcome of @entity1 with ovarian preservation. With more than 100 @entity1 with @entity420 stage (CIS-IIA), none developed an ovarian relapse with a mean follow-up time of 56months. Six articles including 31 @entity1 with ovarian spread were analyzed. At least one of the following risk factor was present in 30/31 (96.7%) of the @entity1 : age >45, FIGO stage >IB, positive lymph nodes, deep stromal invasion, lympho-vascular space invasion, corpus invasion, parametrial invasion or @entity5 size >4cm. CONCLUSION: Ovarian preservation in young @entity1 with early-stage @entity420 is safe. Herein, we propose a set of selection criteria to properly identify candidates for ovarian preservation.

Should ovaries be removed or not in (early-stage) XXXX : a review.

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian metastasis'] @entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma of the uterine cervix', 'adenocarcinoma of the cervix', 'adenocarcinoma of the cervix FIGO'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor']
@entity420 :: (MESH:D000230,Disease) :: ['adenocarcinoma of the uterine cervix']
